Context: Androgens play major roles in prostate cancer initiation and development. In prostate cells, the human uridine diphosphate-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes inactivate androgens.
Objective: We investigated in vivo how UGT2B15 and UGT2B17 expressions are affected during prostate cancer development.
Design: We conducted an observational study of the UGT2B15 and UGT2B17 mRNA and protein levels.
Setting: The study was conducted at Laval University (Québec, Canada) and at the University of British Columbia (Vancouver, Canada).
Patients/participants: Participants were from a cohort of prostate cancer patients from the Hôtel-Dieu de Québec hospital (Québec; mRNA analyses) and from the Vancouver Prostate Centre tissue bank (Vancouver; tissue microarray experiments).
Main Outcome Measures: UGT mRNA and protein levels were determined using real-time PCR and immunohistochemical analyses, respectively.
Results: Both UGT2B15 and UGT2B17 mRNA and protein levels were not significantly associated with Gleason score stratification. However, when protein levels were compared to benign prostatic hyperplasia, UGT2B17 was significantly more abundant in all Gleason-scored tumors. By contrast, UGT2B15 levels were significantly reduced in naive and castration-resistant tumors and undetectable in lymph node metastases. Finally, UGT2B17 proteins were 5-fold more abundant in metastases than in benign samples.
Conclusions: The current study reveals that UGT2B15 and UGT2B17 are differentially regulated during prostate cancer progression. Furthermore, this study also identifies the UGT2B15 gene as a negatively regulated target gene in castration-resistant prostate cancer and lymph node metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2011-2064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2'--Glucuronide Formation as a Selective UGT2B4 Probe Reaction.
Drug Metab Dispos
September 2024
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut.
UGT2B4 is a highly expressed drug-metabolizing enzyme in the liver contributing to the glucuronidation of several drugs. To enable quantitatively assessing UGT2B4 contribution toward metabolic clearance, a potent and selective UGT2B4 inhibitor that can be used for reaction phenotyping was sought. Initially, a canagliflozin-2'--glucuronyl transferase activity assay was developed in recombinant UGT2B4 and human liver microsomes (HLM) [±2% bovine serum albumin (BSA)].
View Article and Find Full Text PDFComparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs.
Pharm Res
August 2024
Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, WA, 99202, USA.
Purpose: Predicting the quantitative fraction of glucuronidation (f) by individual UDP-glucuronosyltransferase enzymes (UGTs) is challenging due to the lack of selective inhibitors and inconsistent activity of recombinant UGT systems (rUGTs). Our study compares the relative expression versus activity factors (REF versus RAF) to predict f based on rUGT data to human liver and intestinal microsomes (HLM and HIM).
Methods: REF scalars were derived from a previous in-house proteomics study for eleven UGT enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17), whereas RAF was calculated by measuring activities in rUGTs to microsomes of selective UGT probe substrates.
Development and Evaluation of Ontogeny Functions of the Major UDP-Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations.
J Clin Pharmacol
October 2024
Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, USA.
Uridine 5'-diphospho-glucuronosyltransferases (UGTs) demonstrate variable expression in the pediatric population. Thus, understanding of age-dependent maturation of UGTs is critical for accurate pediatric pharmacokinetics (PK) prediction of drugs that are susceptible for glucuronidation. Ontogeny functions of major UGTs have been previously developed and reported.
View Article and Find Full Text PDFComparative metabolism of fargesin in human, dog, monkey, mouse, and rat hepatocytes.
Toxicol Res
January 2024
College of Pharmacy and BK21 Four-sponsored Advanced Program for SmartPharma Leaders, The Catholic University of Korea, Bucheon, 14662 Republic of Korea.
Article Synopsis
- Fargesin, a compound from Flos Magnoliae, has various beneficial effects including anti-inflammatory and anti-oxidative properties; its metabolism was studied in several species' liver cells using advanced mass spectrometry.
- The study found that fargesin undergoes moderate-to-extensive metabolism, producing three phase 1 metabolites and 11 phase 2 metabolites through specific liver enzymes.
- Insights from the research clarify how fargesin is processed in the human body, contributing to our understanding of its pharmacokinetics and potential drug interactions.
Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases.
Chem Biol Interact
August 2023
School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, 124221, China. Electronic address:
Tucatinib is known as a tyrosine kinase inhibitor (TKI), which has been commonly approved for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. However, there haven't been systematic study about the inhibition of tucatinib on UDP-Glucuronosyltransferases (UGTs) and the potential risk of drug-drug interactions (DDIs). In present study, we aimed to systematically investigate the inhibition of tucatinib on recombinant human UGTs and pooled human liver microsomes (HLMs), and to quantitatively evaluate its potential risk of DDIs by in vitro-in vivo extrapolation (IVIVE).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!